+ More Filters

Reset Filters

Title

Funding Organization

Funding Type

Eligible Country

Deadline

Other (Select all that apply)

Show Expired Programs

Show Verified Programs

Not Verified

Brain Health Medicines Scholar Award

Harrington Discovery Institute

The Brain Health Medicine Scholars selection committee seeks:

Discoveries demonstrating rigorous science, creativity, innovation, and potential for clinical impact
Any therapeutic modality
Novel, validated targets

This call is currently open for submissions. Applications can be submitted at any time and will be reviewed on a quarterly basis. Deadlines to submit an application for review are March 31, June 30, September 30 and December 31 annually. Applicants will be notified with the results of the application review prior to the next submission deadline.

The Brain Health Medicines Scholar Award provides funding and drug development support to researchers whose work aims to treat, prevent or cure Alzheimer's disease and related dementias. The award includes:

One-year grant
$100,000 with appropriate justification
Potential to renew for a second year based on milestones achieved
Dedicated Project Manager for the duration of the award
Drug development, commercial strategy and business development support from Harrington's Therapeutics Development Center experts
Opportunity to quality for up to $400,000 in additional funding and drug development support

AI Based Application Success Predictor

1. Strong translational therapeutic focus

The most competitive applications directly address:

therapeutic development,
drug discovery,
biologics,
gene therapies,
precision medicine,
rare disease therapeutics,
translational oncology,
neurodegeneration,
regenerative medicine.

Harrington programs specifically seek discoveries that can move from academia into clinical practice.

2. Clear pathway toward clinical application

One of the strongest predictors of success is:

realistic therapeutic development plans,
translational feasibility,
clinically actionable targets,
drug-development readiness,
commercialization potential.

The institute explicitly prioritizes projects capable of advancing toward patients and clinical translation.

3. Novel, validated biological targets

Competitive proposals commonly feature:

novel therapeutic targets,
strong mechanistic rationale,
validated disease biology,
differentiated therapeutic approaches,
high unmet medical need.

The Oxford-Harrington programs specifically highlight “novel, validated targets” as a key review priority.

4. Strong preliminary and proof-of-concept data

Successful applications usually include:

pilot efficacy data,
translational feasibility studies,
biomarker validation,
preclinical therapeutic evidence,
disease-model validation.

Because Harrington programs are highly translational, robust feasibility evidence substantially improves competitiveness.

5. Innovation and high-risk/high-reward science

Highly competitive projects often involve:

first-in-class therapeutics,
cell and gene therapies,
RNA therapeutics,
precision medicine,
AI-assisted drug discovery,
novel biologics,
advanced translational platforms.

Harrington explicitly encourages breakthrough innovation with major clinical potential.

6. Strong commercialization and IP potential

A distinctive Harrington-specific predictor is:

strong intellectual property strategy,
patent positioning,
commercial scalability,
industry partnership potential.

The Oxford-Harrington award guidance explicitly references commercialization potential and IP strength as important evaluation criteria.

7. Strong multidisciplinary translational team

High-scoring projects frequently involve:

physician-scientists,
translational biologists,
medicinal chemists,
bioengineers,
clinical investigators,
regulatory experts,
industry collaborators.

Collaborative translational ecosystems are highly valued.

8. Access to drug-development infrastructure

Competitive applicants often demonstrate access to:

GMP facilities,
medicinal chemistry,
translational core facilities,
animal models,
clinical trial infrastructure,
bioinformatics platforms.

Harrington programs specifically provide therapeutic-development support and infrastructure access.

9. Strong investigator track record

Important predictors include:

impactful publications,
prior translational achievements,
therapeutic-development experience,
prior grant success,
evidence of independent innovation leadership.

Physician-scientist leadership is particularly valued across Harrington programs.

10. Potential for scalable future investment

Reviewers strongly favor projects likely to:

attract venture or pharma partnerships,
generate NIH/foundation funding,
progress toward IND-enabling studies,
enter clinical trials,
create startup or licensing opportunities.

Harrington programs can provide additional acceleration funding and investment support for highly promising projects.

Common Reasons for Rejection

Frequent reviewer concerns include:

weak translational pathway,
insufficient therapeutic differentiation,
inadequate proof-of-concept data,
poor commercialization strategy,
weak IP positioning,
unrealistic development timelines,
insufficient clinical relevance,
lack of feasibility evidence.

Specialties

Public Health

Eligibility Requirements

MD or PhD (or equivalent)
Faculty position at an accredited academic medical center, university or research institution in the US, Canada, or UK, and conduct the majority of their research at that institution
A project must have a single Principal Investigator (PI) who will be named the Scholar and who is responsible for project oversight and financial management. The PI may engage collaborators, core labs or commercial CROs to execute any portion of the project.
Past recipients of Harrington awards may submit new and distinct proposals, but may not seek additional support for previously funded projects.

Sponsor Details

Sponsor Institute/Organizations: Harrington Discovery Institute

Sponsor Type: Corporate/Non-Profit

Address: 11407 Euclid Ave. Floor 2 Cleveland, OH 44106

Legal & Affiliation Disclaimer

Affiliation Disclaimer: Trialect operates independently and is not affiliated with, endorsed by, or supported by any sponsors or organizations posting on the GrantsBoard platform. As an independent aggregator of publicly available funding opportunities, Trialect provides equal access to information for all users without endorsing any specific funding source, content, organization, or sponsor. Trialect assumes no responsibility for the content posted by sponsors or third parties.

Subscription Disclaimer: Upon logging into Trialect, you may choose to SUBSCRIBE to GrantsBoard for timely notifications of funding opportunities and to access exclusive benefits, such as priority alerts, reminders, personalized recommendations, and additional application support. However, users are advised to contact sponsors directly for any questions and are not required to subscribe to engage with funding opportunities.

Content Ownership and Copyright Disclaimer: Trialect respects the intellectual property rights of all organizations and individuals. All content posted on GrantsBoard is provided solely for informational purposes and remains the property of the original owners. Trialect does not claim ownership of, nor does it have any proprietary interest in, content provided by third-party sponsors. Users are encouraged to verify content and ownership directly with the posting sponsor.

Fair Use Disclaimer: The information and content available on GrantsBoard are compiled from publicly accessible sources in alignment with fair use principles under U.S. copyright law. Trialect serves as an aggregator of this content, offering it to users in good faith and with the understanding that it is available for public dissemination. Any organization or individual who believes their intellectual property rights have been violated is encouraged to contact us for prompt resolution.

Third-Party Posting Responsibility Disclaimer: Trialect is a neutral platform that allows third-party sponsors to post funding opportunities for informational purposes only. Sponsors are solely responsible for ensuring that their postings comply with copyright, trademark, and other intellectual property laws. Trialect assumes no liability for any copyright or intellectual property infringements in third-party content and will take appropriate action to address any substantiated claims.

Accuracy and Verification Disclaimer: Trialect makes no warranties regarding the accuracy, completeness, or reliability of the information provided by sponsors. Users are advised to verify the details of any funding opportunity directly with the sponsor before taking action. Trialect cannot be held liable for any discrepancies, omissions, or inaccuracies in third-party postings.

Notice and Takedown Policy: Trialect is committed to upholding copyright law and protecting the rights of intellectual property owners. If you believe that content on GrantsBoard infringes your copyright or intellectual property rights, please contact us with detailed information about the claim. Upon receipt of a valid notice, Trialect will promptly investigate and, where appropriate, remove or disable access to the infringing content.

View Funding Opportunity